Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Aviation, Space, and Environmental Medicine|November 1, 1983
Neurophysiological effects of -X impact accelerationM S Weiss, M D Berger
Circulation|October 1, 1988
Spontaneous compared with induced onset of sustained ventricular tachycardiaM D Berger, H L Waxman, A E Buxton, et al.
Biochemical and Biophysical Research Communications|August 31, 2001
Design and evaluation of a tryptophanless RecA protein with wild type activityM D Berger, A M Lee, R A Simonette, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 18, 2020
Choice of first line systemic treatment in pancreatic cancer among national expertsM Glatzer, D Horber, M Montemurro, et al.
The Pharmacogenomics Journal|August 10, 2016
Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patientsY Ning, W Zhang, D L Hanna, et al.
Aviation, Space, and Environmental Medicine|December 1, 1983
Evoked potential studies of the effects of impact acceleration on the motor nervous systemB Saltzberg, W D Burton, N R Burch, et al.
Journal of Translational Medicine|December 2, 2024
Combining immunoscore and tumor budding in colon cancer: an insightful prognostication based on the tumor-host interfaceT S Haddad, J M Bokhorst, M D Berger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trialsM D Berger, S Stintzing, V Heinemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancerM Suenaga, M Schirripa, S Cao, et al.
The Pharmacogenomics Journal|October 5, 2016
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trialsA Sebio, S Stintzing, V Heinemann, et al.
Pageof 2